SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

05 May 2023 Evaluate
A fair growth of 10.87% in the revenue at Rs. 8488.60 millions was reported in the March 2023 quarter as compared to Rs. 7656.30 millions during year-ago period.Net profit declined -13.07% to Rs. 1172.10 millions from Rs. 1348.40 millions.A decline of 1812.80 millions was observed in the OP in the quarter ended March 2023 from 2155.70 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 8488.60 7656.30 10.87 34112.70 31406.40 8.62 34112.70 31406.40 8.62
Other Income 367.50 284.20 29.31 1327.50 1397.30 -5.00 1327.50 1397.30 -5.00
PBIDT 1812.80 2155.70 -15.91 8320.30 10306.20 -19.27 8320.30 10306.20 -19.27
Interest 12.10 71.80 -83.15 52.30 91.20 -42.65 52.30 91.20 -42.65
PBDT 1800.70 2083.90 -13.59 8268.00 10215.00 -19.06 8268.00 10215.00 -19.06
Depreciation 321.10 300.90 6.71 1269.50 1209.60 4.95 1269.50 1209.60 4.95
PBT 1479.60 1783.00 -17.02 6998.50 9005.40 -22.29 6998.50 9005.40 -22.29
TAX 307.50 434.60 -29.25 1411.30 1806.80 -21.89 1411.30 1806.80 -21.89
Deferred Tax -84.50 -34.90 142.12 -29.30 95.10 -130.81 -29.30 95.10 -130.81
PAT 1172.10 1348.40 -13.07 5587.20 7198.60 -22.38 5587.20 7198.60 -22.38
Equity 252.70 171.70 47.18 252.70 171.70 47.18 252.70 171.70 47.18
PBIDTM(%) 21.36 28.16 -24.15 24.39 32.82 -25.67 24.39 32.82 -25.67

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×